Prime Highlights
- Pfizer and Innovent signed a $10.5 billion licensing deal to jointly develop 12 early-stage cancer drug programs.
- The partnership splits development responsibilities, with Innovent leading early trials before Pfizer takes global control.
Key Facts
- The deal includes a $650 million upfront payment and up to $9.85 billion in milestone-based payments.
- The collaboration reflects a rising trend of global pharma companies sourcing oncology innovation from China.
Background
U.S. drugmaker Pfizer has agreed to a major global licensing and collaboration deal with China’s Innovent Biologics to develop a group of early-stage cancer treatments. The agreement is valued at up to $10.5 billion and covers 12 experimental oncology programs. It includes antibody-drug conjugates and multi-specific antibody therapies aimed at improving cancer treatment outcomes. The partnership shows growing cooperation between global pharma firms and Chinese biotech companies.
Under the agreement, Innovent will lead development of all 12 programs through Phase 1 clinical trials before Pfizer takes over global development. The deal includes a $650 million upfront payment to Innovent and up to $9.85 billion in milestone payments tied to development, regulatory approvals and commercial success. The collaboration is structured in three parts. Four programs will be co-developed and co-commercialised in the United States and
Europe with profit sharing, while Innovent retains rights in Greater China. Four other programs grant Pfizer exclusive rights outside Greater China, and the remaining four give Pfizer global rights with full development responsibility.
The deal reflects a wider surge in China’s biotech licensing activity, especially in oncology. Global drugmakers are increasingly turning to Chinese firms for innovative drug candidates. Industry data shows that the value of such deals in Greater China has risen sharply in recent years, reaching a record level last year. Analysts expect this momentum to continue as demand for advanced cancer therapies grows worldwide today.
Pfizer’s oncology portfolio is partnered with Chinese biotech companies. The deal combines early-stage risk and experience, accelerating global development and adding experimental cures.
